Objective: To describe emergent therapies, such as rifaximin, nitazoxanide, intravenous immunoglobulin (IVIG), tinidazole, tolevamer, and the possible use of a vaccine, in Clostridium difficile ...

Purpose: Current and future treatment modalities for Clostridium difficile-associated disease (CDAD) are reviewed. Conclusion: CDAD is a major concern for health care systems and clinicians.

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

H. pylori infections occur across the world due to exposure to saliva or stool in contaminated water or food. Learn how the ...

The following is a summary of “Rational design of live biotherapeutic products for the prevention of Clostridioides difficile infection,” published in the September 2024 issue of Infectious Disease by ...

Even if outbreaks of acne cannot be eliminated, conventional treatment can provide relief. The best treatments inhibit sebum production, limit bacterial growth, encourage shedding of skin cells to ...

Although ibogaine gained popularity in the U.S. and Europe in the 1980s as a non-addictive treatment for drug dependency, it’s still classified as a Schedule I substance under the Controlled ...

Antimicrobial drugs are widely used around the world to treat infections. However, the overuse of antimicrobials has resulted ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

Simon Parkinson had no coordination or movement in his right arm and leg when he was restrained and transported to hospital ...